Prostate Cancer Progression:: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells

Olaniyi Ogundiya; Helen Whiteland; U. K. Shah; O. Bodger; J. Verma; C. Coker; H. Kynaston; S. Doak

doi:10.1016/j.ijsu.2018.05.725

Abstract

Aim: Experimental studies have suggested that the antitumor properties of aspirin are attributed to its direct inhibition of cyclooxygenase-2 (COX-2) activity. However, other studies have also suggested that non-COX pathways could be of importance. We studied the effect of aspirin, and its active metabolite sodium salicylate on prostate cancer cell proliferation and cell cycle analysis.

Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. After treatment, proportion of cells in G0/G1, S, and G2/M phases of the cell cycle were quantitated by fluorescence-activated cell sorting.

Result: Our results indicate that aspirin inhibite cell cycle progression in prostate cancer cell. We observed a G0/G1 cell arrest in both PC3 and DU145 with each aspirin treatment as the highest proportion of cells were in G0/G1.The active metabolite, sodium salicylate also indicated a G0/G1 cell arrest in both PC3 and DU145.

Conclusion: This study provides evidence that aspirin inhibits cell cycle progression in prostate cancer cells, which suggests that aspirin may be relevant to prostate cancer progression

Original language	English
Pages	S11-S12
Number of pages	2
DOIs	https://doi.org/10.1016/j.ijsu.2018.05.725
Publication status	E-pub ahead of print - 02 Aug 2018
Event	Association of Surgeons In Training International Surgical Conference 2018 - Edinburgh International conference Centre, Edinburgh, United Kingdom of Great Britain and Northern Ireland Duration: 06 Apr 2018 → 08 Apr 2018

Conference

Conference	Association of Surgeons In Training International Surgical Conference 2018
Abbreviated title	ASiT
Country/Territory	United Kingdom of Great Britain and Northern Ireland
City	Edinburgh
Period	06 Apr 2018 → 08 Apr 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ijsu.2018.05.725

Permanent link

Persistent link

Cite this

Ogundiya, O., Whiteland, H., Shah, U. K., Bodger, O., Verma, J., Coker, C., Kynaston, H., & Doak, S. (2018). Prostate Cancer Progression: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells. S11-S12. Abstract from Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, United Kingdom of Great Britain and Northern Ireland. Advance online publication. https://doi.org/10.1016/j.ijsu.2018.05.725

@conference{7a0812005a374a5d89e14202ed3ecaea,

title = "Prostate Cancer Progression:: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells",

abstract = "Aim: Experimental studies have suggested that the antitumor properties of aspirin are attributed to its direct inhibition of cyclooxygenase-2 (COX-2) activity. However, other studies have also suggested that non-COX pathways could be of importance. We studied the effect of aspirin, and its active metabolite sodium salicylate on prostate cancer cell proliferation and cell cycle analysis. Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. After treatment, proportion of cells in G0/G1, S, and G2/M phases of the cell cycle were quantitated by fluorescence-activated cell sorting. Result: Our results indicate that aspirin inhibite cell cycle progression in prostate cancer cell. We observed a G0/G1 cell arrest in both PC3 and DU145 with each aspirin treatment as the highest proportion of cells were in G0/G1.The active metabolite, sodium salicylate also indicated a G0/G1 cell arrest in both PC3 and DU145. Conclusion: This study provides evidence that aspirin inhibits cell cycle progression in prostate cancer cells, which suggests that aspirin may be relevant to prostate cancer progression",

author = "Olaniyi Ogundiya and Helen Whiteland and Shah, \{U. K.\} and O. Bodger and J. Verma and C. Coker and H. Kynaston and S. Doak",

year = "2018",

month = aug,

day = "2",

doi = "10.1016/j.ijsu.2018.05.725",

language = "English",

pages = "S11--S12",

note = "Association of Surgeons In Training International Surgical Conference 2018, ASiT ; Conference date: 06-04-2018 Through 08-04-2018",

}

Ogundiya, O, Whiteland, H, Shah, UK, Bodger, O, Verma, J, Coker, C, Kynaston, H & Doak, S 2018, 'Prostate Cancer Progression: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells', Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, United Kingdom of Great Britain and Northern Ireland, 06 Apr 2018 - 08 Apr 2018 pp. S11-S12. https://doi.org/10.1016/j.ijsu.2018.05.725

Prostate Cancer Progression: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells. / Ogundiya, Olaniyi; Whiteland, Helen; Shah, U. K. et al.
2018. S11-S12 Abstract from Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, United Kingdom of Great Britain and Northern Ireland.

Research output: Contribution to conference › Abstract › peer-review

TY - CONF

T1 - Prostate Cancer Progression:

T2 - Association of Surgeons In Training International Surgical Conference 2018

AU - Ogundiya, Olaniyi

AU - Whiteland, Helen

AU - Shah, U. K.

AU - Bodger, O.

AU - Verma, J.

AU - Coker, C.

AU - Kynaston, H.

AU - Doak, S.

PY - 2018/8/2

Y1 - 2018/8/2

N2 - Aim: Experimental studies have suggested that the antitumor properties of aspirin are attributed to its direct inhibition of cyclooxygenase-2 (COX-2) activity. However, other studies have also suggested that non-COX pathways could be of importance. We studied the effect of aspirin, and its active metabolite sodium salicylate on prostate cancer cell proliferation and cell cycle analysis. Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. After treatment, proportion of cells in G0/G1, S, and G2/M phases of the cell cycle were quantitated by fluorescence-activated cell sorting. Result: Our results indicate that aspirin inhibite cell cycle progression in prostate cancer cell. We observed a G0/G1 cell arrest in both PC3 and DU145 with each aspirin treatment as the highest proportion of cells were in G0/G1.The active metabolite, sodium salicylate also indicated a G0/G1 cell arrest in both PC3 and DU145. Conclusion: This study provides evidence that aspirin inhibits cell cycle progression in prostate cancer cells, which suggests that aspirin may be relevant to prostate cancer progression

AB - Aim: Experimental studies have suggested that the antitumor properties of aspirin are attributed to its direct inhibition of cyclooxygenase-2 (COX-2) activity. However, other studies have also suggested that non-COX pathways could be of importance. We studied the effect of aspirin, and its active metabolite sodium salicylate on prostate cancer cell proliferation and cell cycle analysis. Method: We exposed PNT2 (normal prostate), DU145 (prostatic brain metastasis), PC3 (prostatic bone metastasis) to six physiologically relevant doses (0- 10mM) of aspirin and sodium salicylate. After treatment, proportion of cells in G0/G1, S, and G2/M phases of the cell cycle were quantitated by fluorescence-activated cell sorting. Result: Our results indicate that aspirin inhibite cell cycle progression in prostate cancer cell. We observed a G0/G1 cell arrest in both PC3 and DU145 with each aspirin treatment as the highest proportion of cells were in G0/G1.The active metabolite, sodium salicylate also indicated a G0/G1 cell arrest in both PC3 and DU145. Conclusion: This study provides evidence that aspirin inhibits cell cycle progression in prostate cancer cells, which suggests that aspirin may be relevant to prostate cancer progression

U2 - 10.1016/j.ijsu.2018.05.725

DO - 10.1016/j.ijsu.2018.05.725

M3 - Abstract

SP - S11-S12

Y2 - 6 April 2018 through 8 April 2018

ER -

Ogundiya O, Whiteland H, Shah UK, Bodger O, Verma J, Coker C et al.. Prostate Cancer Progression: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells. 2018. Abstract from Association of Surgeons In Training International Surgical Conference 2018, Edinburgh, United Kingdom of Great Britain and Northern Ireland. Epub 2018 Aug 2. doi: 10.1016/j.ijsu.2018.05.725

Prostate Cancer Progression: Aspirin Causes Cell Cycle Quiescence in Prostate Cancer Cells